Radiation without chemo should remain standard for HNC
7/25/2002 Orlando Johns Hopkins Kimmel Cancer Center Toxicities were significantly higher among patients receiving chemoradiation than for those who received radiation alone. Adding chemotherapy to radiation for advanced head and neck cancer (HNC) treatment does not improve overall survival, according to preliminary results from a multicenter study presented at the 38th Annual Meeting of ASCO here. Although further patient follow-up is needed and additional studies are warranted, we continue to recommend that patients receive the current standard of care surgery followed by radiation alone,” said Arlene Forastiere, MD, professor of oncology and otolaryngology at the Johns Hopkins Kimmel Cancer Center in Baltimore. Early studies suggested that combining certain chemotherapy drugs and radiation may have a synergistic effect in [patients with advanced HNC],” she said. Our current study shows that adding cisplatin to standard radiation treatment does not significantly reduce recurrence.” Forastiere and her colleagues evaluated 459 patients who had high-risk squamous cell carcinomas of the head and neck. After surgery to remove all detectable disease, all patients received 60 to 66 Gy in 30 to 33 fractions over 6.0 to 6.6 weeks. A group of 228 patients were randomly assigned to also receive 100 mg/m2 of IV cisplatin (Platinol, Bristol-Myers Squibb) on days 1, 22 and 43. With a median follow-up of 26.6 months, there was no significant difference in local cancer recurrence between the two groups. The local-regional control rate was 73.8% for patients who received only radiation and 79.2% for those who received chemoradiation. The two-year overall survival [...]